Even still, the pharma deals announced out of the event brought a clear message for the biotech industry. Technology ...

The arc of biotechnology is one of breakthroughs and struggles, writes Tim Hunt, CEO of the Alliance for Regenerative ...

According to the report, titled "India Bioeconomy Report 2025", the bioeconomy sector witnessed a 16-fold expansion in the ...

Q4 2024 Management View Walter Klemp, Chairman and CEO, announced significant progress on the MIRACLE Phase 3 pivotal trial for Annamycin, targeting second-line treatment of relapsed and refractory ...

Supreme Court hearings on GM crops progress, DBT supports GM mustard, BioE3 policy focus, bio-agriculture growth in India.

(RTTNews) - LIXTE Biotechnology Holdings, Inc. (LIXT), on Thursday, announced the latest progress with its proprietary compound, LB-100, for the treatment of ovarian and colorectal cancer.

THIO has gained its generic name and preclinical data on a different form of the cancer drug suggests it could improve ...

PASADENA, Calif, March 27, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

IO Biotech announced that it is on track to submit a Biologics License Application for its investigational cancer vaccine Cylembio® to the FDA by the end of 2025, following the completion of ...

-Started Two New Clinical Trials, Collaborating with MD Anderson and The Netherlands Cancer Institute for Treatment of Ovarian and Colorectal Cancer- -Received Exclusive Patent License Agreement ...